Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis
Rheumatology (Oxford)
.
2024 Mar 1;63(3):e96-e98.
doi: 10.1093/rheumatology/kead479.
Authors
Marco Caminati
1
,
Elena Scarpieri
2
,
Matteo Maule
3
,
Patrick Pinter
4
,
Michele Schiappoli
3
,
Rachele Vaia
3
,
Gianenrico Senna
1
3
Affiliations
1
Department of Medicine, University of Verona and Verona University Hospital, Verona, Italy.
2
School of Specialization in Allergy and Clinical Immunology, Department of Medicine, University of Verona, Verona, Italy.
3
Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy.
4
Unit of Otolaryngology, Head and Neck Department, University of Verona, Verona, Italy.
PMID:
37695303
DOI:
10.1093/rheumatology/kead479
No abstract available
MeSH terms
Antibodies, Monoclonal, Humanized* / therapeutic use
Granulomatosis with Polyangiitis*
Humans
Substances
mepolizumab
dupilumab
Antibodies, Monoclonal, Humanized